Evenity (Romosozumab) Anesthesia and Perioperative Interaction

What Is Romosozumab and Why Does It Matter for Surgery?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual mechanism not seen with any other approved osteoporosis agent. FDA approval was granted in April 2019 for postmenopausal women with osteoporosis at high fracture risk. [1]

The Cardiovascular Boxed Warning

The FDA prescribing label carries a boxed warning stating: "Evenity may increase the risk of myocardial infarction, stroke, and cardiovascular death. In a clinical trial, more serious cardiovascular events occurred in patients treated with Evenity compared to patients treated with alendronate." [1] This language comes directly from the ARCH trial (N=4,093), where romosozumab was associated with a higher rate of adjudicated serious cardiovascular events versus alendronate at 12 months (2.5% vs. 1.9%). [2]

Why Anesthesiologists Need to Know This

General and regional anesthesia carry their own hemodynamic stresses: sympathetic activation during laryngoscopy, blood pressure swings, and postoperative hypercoagulability. Layering the romosozumab cardiovascular signal onto an already hemodynamically stressed surgical patient creates a risk profile that deserves structured preoperative review. The American Heart Association's perioperative cardiac risk framework stratifies patients by baseline cardiac risk before any elective procedure. [3]

The FDA Boxed Warning in Surgical Context

The boxed warning is the single most actionable piece of clinical information for perioperative planning. Romosozumab should not be initiated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months, and the label states that clinicians should "consider whether the benefits outweigh the risks" in patients with other cardiovascular risk factors. [1]

ARCH Trial Data in Detail

The ARCH trial randomized 4,093 postmenopausal women with osteoporosis and at least one prior vertebral fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone. At the primary 24-month endpoint, romosozumab-to-alendronate reduced new vertebral fracture risk by 48% versus alendronate-to-alendronate (6.2% vs. 11.9%, P<0.001). [2] The cardiovascular signal was detected in the first 12-month active treatment phase, not the subsequent alendronate phase.

FRAME Trial Data for Comparison

The FRAME trial (N=7,180) compared romosozumab to placebo and did not show a statistically significant cardiovascular imbalance (0.8% vs. 0.6% in the romosozumab and placebo arms at 12 months). [4] The discrepancy between ARCH and FRAME has been attributed to the active comparator design of ARCH and possible cardioprotective effects of alendronate, not necessarily a direct causal romosozumab effect. [5] Regardless of mechanism, the FDA boxed warning stands and governs clinical decision-making.

Pharmacokinetics Relevant to Perioperative Timing

Half-Life and Clearance

Romosozumab has a mean terminal half-life of approximately 6.4 days after subcutaneous administration. [1] Using the standard five-half-life clearance estimate, the drug reaches negligible plasma concentrations roughly 32 days after the last injection. The monthly dosing interval means that a patient who received their last injection at the start of month 12 will retain detectable drug for approximately five weeks after that final dose.

No Established "Hold" Guideline

No major anesthesia society, including the American Society of Anesthesiologists or the European Society of Anaesthesiology and Intensive Care, has published a specific romosozumab perioperative hold protocol as of the date this article was last reviewed. That absence of guidance does not mean no risk exists. It means clinicians must reason from first principles: cardiovascular boxed warning, half-life of 6.4 days, and patient-specific cardiac risk. [3]

Bone Turnover Marker Timing

Romosozumab produces a rapid and large increase in bone formation markers. Serum procollagen type 1 N-terminal propeptide (P1NP) peaks at approximately month 1 and then returns toward baseline by month 12. Bone resorption marker CTX is suppressed during treatment. [6] After the 12-month course ends, bone turnover markers rebound sharply if no antiresorptive agent is added, which is why sequential therapy with denosumab or a bisphosphonate is standard practice. [7] This marker trajectory does not directly affect surgical bleeding risk but may influence decisions about timing fracture repair relative to the treatment course.

Cardiovascular Risk Assessment Before Surgery

RCRI and MACE Risk

The Revised Cardiac Risk Index (RCRI) is the most widely used preoperative cardiac risk tool. Patients on romosozumab who have two or more RCRI factors (history of ischemic heart disease, heart failure, cerebrovascular disease, insulin-dependent diabetes, renal insufficiency, or high-risk surgery) should have a formal cardiology consultation before elective procedures. [3] The 2014 ACC/AHA guideline on perioperative cardiovascular evaluation, updated in the 2024 revision published in the Journal of the American College of Cardiology, recommends noninvasive stress testing for patients with elevated risk and poor functional capacity. [3]

Specific Questions for the Preoperative Visit

Patients on romosozumab presenting for preoperative evaluation should be asked four targeted questions. First: when was the last injection? Second: has the prescribing clinician been notified about the planned surgery? Third: has the patient experienced any chest pain, dyspnea on exertion, or neurological symptoms since starting therapy? Fourth: what is the patient's underlying cardiovascular risk profile according to the Framingham or ASCVD calculator?

A 2022 analysis in the Journal of Clinical Endocrinology and Metabolism examined cardiovascular event rates across romosozumab trial data and concluded that the absolute risk increase remains small but is concentrated in patients who already carry elevated baseline cardiovascular risk. [8]

Anesthetic Management Considerations

Regional vs. General Anesthesia

No controlled trial has directly compared regional versus general anesthesia outcomes in patients receiving romosozumab. The cardiovascular hemodynamic differences between techniques are well documented: spinal and epidural anesthesia reduce sympathetic tone and can lower mean arterial pressure by 20-30%, while general anesthesia with laryngoscopy transiently elevates heart rate and blood pressure. [9] For a patient with a recent romosozumab-associated cardiovascular concern, neither technique is categorically safer. Anesthetic selection should be individualized based on the procedure type, patient anatomy, and the anesthesiologist's judgment.

Intraoperative Monitoring

Patients with a cardiovascular history who are on or recently completed romosozumab may benefit from invasive arterial line monitoring during intermediate- to high-risk procedures, allowing beat-to-beat blood pressure tracking. A 12-lead ECG within 30 days of surgery is reasonable for any patient with RCRI score above 1. [3]

Drug Interactions in the Operating Room

Romosozumab itself does not undergo hepatic cytochrome P450 metabolism. As a monoclonal antibody, it is catabolized through proteolytic degradation pathways shared by endogenous immunoglobulins. [1] This means traditional pharmacokinetic drug-drug interactions with volatile anesthetics (sevoflurane, desflurane, isoflurane), propofol, ketamine, or neuromuscular blocking agents are not expected. The concern is pharmacodynamic, not pharmacokinetic: the drug's cardiovascular risk profile interacts with the physiologic stresses of anesthesia, not with any specific anesthetic molecule.

Vasopressor and Anticoagulant Considerations

Romosozumab does not affect platelet function or coagulation cascade. [1] Standard regional anesthesia anticoagulant hold protocols (e.g., ASRA guidelines for neuraxial procedures) do not need modification specifically for romosozumab. However, the cardiovascular risk profile may prompt the surgical team to use vasopressors more proactively to maintain mean arterial pressure during hypotensive episodes, given the boxed warning context.

Perioperative Hold and Restart Decision Framework

The following decision framework synthesizes the FDA label, published pharmacokinetics, and cardiovascular risk stratification literature into a practical clinical tool. No single guideline currently provides this level of romosozumab-specific perioperative structure.

Pre-Surgical Assessment (4+ Weeks Before Elective Procedure)

Step 1: Calculate the patient's ASCVD 10-year risk score using the ACC/AHA Pooled Cohort Equations. [10]

Step 2: Identify whether the patient had an MI or stroke within the preceding 12 months. If yes, romosozumab should not have been initiated per the label, escalate to prescribing physician immediately.

Step 3: If ASCVD risk is above 20% or the patient has symptomatic cardiac disease, obtain cardiology clearance before any elective procedure, regardless of romosozumab status.

Step 4: Notify the romosozumab-prescribing clinician (typically an endocrinologist or rheumatologist) about the surgical plan to coordinate the 12-month treatment course, since delaying injections beyond one month disrupts the anabolic window.

Timing the Last Injection Relative to Surgery

The 12-month romosozumab course is time-sensitive. Missing a monthly injection by more than four weeks means the anabolic window is partially lost, and the patient will still require a sequential antiresorptive agent afterward. [7] For low-cardiac-risk patients undergoing elective surgery, the preferred approach is to complete the planned monthly injection on schedule and then allow at least one standard dosing interval (30 days) before the operative date if the procedure carries intermediate or high cardiovascular risk. This approach preserves treatment continuity while creating a pharmacokinetic gap of approximately five half-lives.

For urgent or emergent surgery, romosozumab hold timing is irrelevant. The drug cannot be reversed, has no antagonist, and will have reached its peak pharmacodynamic effect within 24 hours of injection. [1] The anesthesia team should be notified of the active therapy and the cardiovascular boxed warning, and standard high-risk cardiovascular monitoring should be applied.

Post-Surgical Restart

If the 12-month romosozumab course was interrupted by surgery, the prescribing clinician must decide whether to complete remaining injections or transition directly to antiresorptive therapy. The 2020 AACE/ACE Clinical Practice Guidelines for postmenopausal osteoporosis state: "After completing romosozumab therapy, treatment with antiresorptive therapy is recommended to maintain the gains in BMD." [11] Restarting mid-course after a surgical gap has limited evidence; the FRAME and ARCH trials did not model interruption scenarios.

Bone Healing and Fracture Repair in the Surgical Context

Effect of Sclerostin Inhibition on Fracture Healing

Animal models and small human studies suggest that sclerostin inhibition may accelerate fracture healing. A study published in the Journal of Bone and Mineral Research demonstrated that romosozumab accelerated fracture repair in rodent models, increasing callus formation and mechanical strength at four weeks. [12] Whether this translates to meaningful clinical benefit in humans undergoing orthopedic surgery is not yet established in randomized controlled trials.

Elective Orthopedic Procedures

For patients with osteoporosis undergoing elective total hip or knee arthroplasty, the decision to continue versus pause romosozumab involves weighing the anabolic window of the 12-month course against the cardiovascular monitoring required for major orthopedic surgery. A 2021 case series in Bone described outcomes in patients who continued romosozumab through orthopedic procedures without incident, though the sample size was too small (N=12) to draw safety conclusions. [13]

Implant Osseointegration

The anabolic effect of romosozumab on peri-implant bone formation is a theoretically favorable property for joint replacement surgery. Preclinical data published by Ominsky et al. In the Journal of Bone and Mineral Research showed improved implant fixation strength in sclerostin-antibody-treated animals versus controls. [14] This effect has not been studied in randomized human trials.

Alcohol and Evenity: A Separate but Relevant Concern

Direct Pharmacokinetic Interaction

Alcohol does not inhibit or induce the proteolytic pathways that catabolize romosozumab. No pharmacokinetic interaction between ethanol and romosozumab has been identified in the clinical pharmacology section of the FDA label. [1]

Indirect Clinical Concerns

Alcohol consumption above two standard drinks per day is an established independent risk factor for bone loss. A meta-analysis of 17 prospective cohort studies published in Osteoporosis International found that heavy alcohol use (more than two drinks per day) was associated with a 39% increased risk of hip fracture compared to non-drinkers. [15] Patients taking romosozumab for high-risk osteoporosis should be counseled to limit alcohol to no more than one standard drink per day, consistent with the National Institute on Alcohol Abuse and Alcoholism's low-risk drinking guidelines. [16]

Alcohol also increases fall risk, which is the proximate cause of most fragility fractures. The clinical value of romosozumab's BMD gains can be partially offset by alcohol-related fall risk if patients are not counseled appropriately.

Special Populations and Surgical Scenarios

Patients With Prior Stroke or MI

Per the FDA label, romosozumab is contraindicated in patients with MI or stroke in the preceding 12 months. [1] A patient who had a cardiac or cerebrovascular event within that window and is now presenting for elective surgery should not be receiving romosozumab at all. If they are, the prescribing clinician must be contacted before the procedure proceeds.

Patients Transitioning to Denosumab Post-Romosozumab

Many patients completing romosozumab are transitioned to denosumab (Prolia). Denosumab carries its own perioperative considerations, including hypocalcemia risk, particularly in vitamin D-deficient patients undergoing parathyroid or thyroid surgery. [17] The transition drug must be disclosed to the surgical and anesthesia team as part of a complete medication reconciliation.

Postmenopausal Women Over 70

ARCH enrolled women with a mean age of 74 years. Older patients carry higher baseline RCRI scores and higher prevalence of subclinical cardiovascular disease. A 2019 analysis in JAMA Internal Medicine found that 35% of women over 70 undergoing elective non-cardiac surgery had at least one RCRI risk factor. [18] In this demographic, romosozumab-to-surgery sequencing deserves explicit multidisciplinary planning.

Practical Checklist for the Prescribing Clinician

• Confirm no MI or stroke in the preceding 12 months before initiating romosozumab. [1]
• Calculate ASCVD risk at baseline and document it in the patient record.
• At every monthly injection visit, ask the patient about upcoming surgical or procedural plans.
• Notify the surgical team in writing that the patient is on romosozumab and provide the FDA boxed warning language.
• For elective intermediate- or high-risk surgery, aim to schedule the procedure at least 30 days after the last injection to maximize pharmacokinetic clearance.
• After surgery, restart romosozumab only if fewer than three injections remain in the 12-month course and cardiac status permits; otherwise transition to antiresorptive therapy per AACE/ACE guidelines. [11]
• Verify the patient's serum calcium and vitamin D status before and after surgery, as hypocalcemia can occur with any bone-active agent in the perioperative setting. [17]